BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study
Source ↗
👁 0
💬 0
The companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.
Comments (0)